Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.
复制标题

DOI:
10.1016/j.vaccine.2008.10.051
复制
发表时间:
2009-01-07
期刊:
影响因子:
5.5
通讯作者:
NIAID HIV Vaccine Trials Network
NIAID HIV Vaccine Trials Network
中科院分区:
医学3区
文献类型:
--
作者:
Spearman P;Kalams S;Elizaga M;Metch B;Chiu YL;Allen M;Weinhold KJ;Ferrari G;Parker SD;McElrath MJ;Frey SE;Fuchs JD;Keefer MC;Lubeck MD;Egan M;Braun R;Eldridge JH;Haynes BF;Corey L;NIAID HIV Vaccine Trials Network

文献摘要

参考文献

被引文献

相似文献

There is an urgent need for a vaccine capable of preventing HIV infection or the development of HIV-related disease. A number of approaches designed to stimulate HIV-specific CD8+ cytotoxic T cell responses together with helper responses are presently under evaluation. In this phase 1, multi-center, placebo-controlled trial, we tested the ability of a novel multi-epitope peptide vaccine to elicit HIV-specific immunity. To enhance the immunogenicity of the peptide vaccine, half of the vaccine recipients received recombinant GM-CSF protein as a co-adjuvant. The vaccine was safe; tolerability was moderate, with a number of adverse events related to local injection site reactogenicity. Anti-GM-CSF antibody responses developed in the majority of GM-CSF recipients but were not associated with adverse hematologic events. The vaccine was only minimally immunogenic. Six of 80 volunteers who received vaccine developed HIV-specific responses as measured by interferon-gamma ELISPOT assay, and measurable responses were transient. This study failed to demonstrate that GM-CSF can substantially improve the overall weak immunogenicity of a multiepitope peptide-based HIV vaccine.
DOI: 10.1046/j.1365-2893.1999.00180.x
发表时间: 1999-09-01
影响因子: 2.5
作者:
Kapoor, D;Aggarwal, SR;Sarin, SK
通讯作者: Sarin, SK
DOI: 10.1034/j.1600-0684.2002.02008.x
发表时间: 2002-08-01
影响因子: 0.7
作者:
O'Neill, E;Martinez, I;Kraiselburd, E
通讯作者: Kraiselburd, E
DOI: 10.1016/s0264-410x(01)00469-8
发表时间: 2002-01-31
期刊: VACCINE
影响因子: 5.5
作者:
Follador, I;Araujo, C;Carvalho, EM
通讯作者: Carvalho, EM
DOI: 10.1128/jvi.74.4.1694-1703.2000
发表时间: 2000-02-01
影响因子: 5.4
作者:
Gahéry-Ségard, H;Pialoux, G;Guillet, JG
通讯作者: Guillet, JG
DOI: 10.1093/infdis/173.2.330
发表时间: 1996-02-01
影响因子: 6.4
作者:
Gorse, GJ;Keefer, MC;Fast, PE
通讯作者: Fast, PE